2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Melanoma Updates: Optimal Dosing Schedule of Neoadjuvant Ipi + Nivo, Adjuvant Pembro in Resected High-Risk Stage III, Adjuvant Dabrafenib + Trametinib in BRAF V600E Stage III, Pembro vs. Ipi in Advanced Melanoma

91 views
August 25, 2020
Comments 0
Login to view comments. Click here to Login